Market closed
Xilio Therapeutics/XLO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xilio Therapeutics
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Ticker
XLO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
73
Website
XLO Metrics
BasicAdvanced
$41M
Market cap
-
P/E ratio
-$1.49
EPS
-0.06
Beta
-
Dividend rate
Price and volume
Market cap
$41M
Beta
-0.06
52-week high
$2.89
52-week low
$0.49
Average daily volume
148K
Financial strength
Current ratio
2.019
Quick ratio
1.94
Long term debt to equity
22.642
Total debt to equity
26.003
Interest coverage (TTM)
-166.76%
Management effectiveness
Return on assets (TTM)
-45.75%
Return on equity (TTM)
-130.03%
Valuation
Price to revenue (TTM)
17.268
Price to book
1.22
Price to tangible book (TTM)
1.22
Price to free cash flow (TTM)
-2.344
Growth
Earnings per share change (TTM)
-51.46%
3-year earnings per share growth (CAGR)
-76.23%
What the Analysts think about XLO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Xilio Therapeutics stock.
XLO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
XLO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
XLO News
AllArticlesVideos
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
GlobeNewsWire·3 weeks ago
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Xilio Therapeutics stock?
Xilio Therapeutics (XLO) has a market cap of $41M as of October 26, 2024.
What is the P/E ratio for Xilio Therapeutics stock?
The price to earnings (P/E) ratio for Xilio Therapeutics (XLO) stock is 0 as of October 26, 2024.
Does Xilio Therapeutics stock pay dividends?
No, Xilio Therapeutics (XLO) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next Xilio Therapeutics dividend payment date?
Xilio Therapeutics (XLO) stock does not pay dividends to its shareholders.
What is the beta indicator for Xilio Therapeutics?
Xilio Therapeutics (XLO) has a beta rating of -0.06. This means that it has an inverse relation to market volatility.